Flinton Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Flinton Capital Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$554K	Hold	1,664	–	–	0.02%	427
2019 Q2	$520K	Hold	1,664	–	–	0.02%	463
2019 Q1	$509K	Sell	1,664 -320	-16%	-$86.4K	0.02%	458
2018 Q4	$461K	Sell	1,984 -80	-4%	-$21.5K	0.02%	443
2018 Q3	$646K	Buy	2,064 +704	+52%	+$219K	0.02%	419
2018 Q2	$392K	Hold	1,360	–	–	0.01%	482
2018 Q1	$340K	Hold	1,360	–	–	0.01%	516
2017 Q4	$325K	Buy	1,360 +128	+10%	+$31K	0.01%	539
2017 Q3	$274K	Buy	1,232 +144	+13%	+$32.4K	0.01%	537
2017 Q2	$246K	Buy	1,088 +448	+70%	+$97.6K	0.01%	528
2017 Q1	$128K	Buy	640 +96	+18%	+$18.5K	﹤0.01%	579
2016 Q4	$99K	Buy	+544	New	+$92.7K	﹤0.01%	596

Other funds holding BIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Flinton Capital Management's BIO Position: Q3 2019 in Review

Flinton Capital Management held its Bio-Rad Laboratories Class A (BIO) position steady in Q3 2019 at 1,664 shares worth $554K. The position accounts for 0.02% of the portfolio, ranked #427.

Flinton Capital Management first reported a position in BIO in Q4 2016 and has held it in 12 quarters since. The position peaked at $646K in Q3 2018. 354 funds tracked by Wall St. Rank hold BIO as of Q3 2019.

Flinton Capital Management held 1,664 shares of Bio-Rad Laboratories Class A worth $554K as of Q3 2019.
Flinton Capital Management left its Bio-Rad Laboratories Class A share count unchanged in Q3 2019.
Bio-Rad Laboratories Class A made up 0.02% of Flinton Capital Management's portfolio in Q3 2019, its #427 holding.
Flinton Capital Management first reported a position in Bio-Rad Laboratories Class A in Q4 2016 and has held it in 12 quarters since.
Flinton Capital Management's Bio-Rad Laboratories Class A position peaked at $646K in Q3 2018.
354 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2019.

Based on Flinton Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.